PQA: Developing Measures for Medications
Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's origins as a measure developer during the PQA Annual Meeting in Baltimore, MD.
During the PQA Annual Meeting in Baltimore, MD, Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's recently-developed measures on behalf of CMS.
Laura Cranston, RpH: So, PQA as a measure developer initially focused on developing medication related measures on behalf of CMS for use of the Medicare Part D program. As our mission continues to evolve, PQA is now developing measures, for example, that look at drug therapy resolution following a medication therapy management session. And this is not strictly limited to Medicare. The measure that we just endorsed today can also be used in commercial populations as well.
